Literature DB >> 14507245

Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women.

Kaoru Hirose1, Tatsuya Toyama, Hiroji Iwata, Toshiro Takezaki, Nobuyuki Hamajima, Kazuo Tajima.   

Abstract

To evaluate the effects of glucose metabolism related factors, such as insulin and insulin-like growth-factors (IGFs), on breast cancer development among Japanese women, we conducted a case-referent study comparing 187 women presenting with operable breast cancer and 190 women of the same age having no breast cancer. Odds ratios (OR) and 95% confidence intervals (95%CI) were determined by multiple logistic regression analysis. In the present study, no association in risk was observed with increasing levels of IGF-I or IGF binding protein-3 (IGFBP-3), before or after adjustment these factors. However, a suggestion of a positive association of an increased breast cancer risk was evident in postmenopausal women with elevated plasma insulin levels, particularly those with BMI>23.07. The OR for plasma insulin in the top tertile was 4.48 (95%CI:1.07-18.7) compared to the bottom tertile. For C-peptide, there was a similar positive association, with a corresponding OR of 2.28. In addition, we observed strong links between plasma insulin, C-peptide levels and estrogen receptor (ER) negative breast cancer, with ORs of 2.79(95%CI:1.09-7.16), and 2.52 (95%CI:0.91-6.97) respectively, for the top versus bottom tertiles. In conclusion, the present study suggested that plasma insulin level is a predictor of postmenopausal breast cancer in obese women and ER negative breast cancer. Additional studies are needed to clarify the role of glucose metabolism pathways in breast cancer development and interaction of IGF systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14507245

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  13 in total

1.  The effect of physiological concentrations of sex hormones, insulin, and glucagon on growth of breast and prostate cells supplemented with unmodified human serum.

Authors:  Amin Esfahani; Cyril W C Kendall; Balachandran Bashyam; Michael C Archer; David J A Jenkins
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-10-07       Impact factor: 2.416

Review 2.  Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer.

Authors:  Darren Micallef; Sarah Micallef; Pierre Schembri-Wismayer; Jean Calleja-Agius
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-12-01

3.  Relationship between diabetes and risk of second primary contralateral breast cancer.

Authors:  Christopher I Li; Janet R Daling; Mei-Tzu C Tang; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

Review 4.  Interplay between insulin resistance and estrogen deficiency as co- activators in carcinogenesis.

Authors:  Zsuzsanna Suba
Journal:  Pathol Oncol Res       Date:  2011-10-09       Impact factor: 3.201

5.  Serum levels of leptin, insulin, and lipids in relation to breast cancer in china.

Authors:  Cunzhi Han; Hong-Tao Zhang; Lili Du; Xiuying Liu; Jiexian Jing; Xianwen Zhao; Xuan Yang; Baoguo Tian
Journal:  Endocrine       Date:  2005-02       Impact factor: 3.633

6.  Plasma C-peptide, mammographic breast density, and risk of invasive breast cancer.

Authors:  Thomas P Ahern; Susan E Hankinson; Walter C Willett; Michael N Pollak; A Heather Eliassen; Rulla M Tamimi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10       Impact factor: 4.254

7.  Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss.

Authors:  José Manuel Fernández-Real; Javier A Menendez; Gema Frühbeck; José María Moreno-Navarrete; Alejandro Vazquez-Martín; Wifredo Ricart
Journal:  Nutr Metab (Lond)       Date:  2010-02-25       Impact factor: 4.169

8.  Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study.

Authors:  C Agnoli; F Berrino; C A Abagnato; P Muti; S Panico; P Crosignani; V Krogh
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-04-10       Impact factor: 4.222

Review 9.  Hyperinsulinemia in Obesity, Inflammation, and Cancer.

Authors:  Anni M Y Zhang; Elizabeth A Wellberg; Janel L Kopp; James D Johnson
Journal:  Diabetes Metab J       Date:  2021-03-29       Impact factor: 5.893

Review 10.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.